Laval, Canada

Francis Arhin

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: The Medicines Company. Active years: 2017.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Francis Arhin

Introduction

Francis Arhin is a notable inventor based in Laval, Canada. He has made significant contributions to the field of medicine, particularly in the treatment of bacterial infections. His innovative approach combines existing antibiotics to enhance their effectiveness.

Latest Patents

Francis Arhin holds a patent for "Methods for treating bacterial infections using oritavancin and polymyxins." This patent discloses methods of treating bacterial infections in a subject using a synergistic combination of oritavancin and a polymyxin. His work in this area has the potential to improve treatment outcomes for patients suffering from bacterial infections.

Career Highlights

Throughout his career, Francis Arhin has worked with prominent companies in the pharmaceutical industry. He has been associated with The Medicines Company and Melinta Therapeutics, Inc., where he contributed to the development of innovative treatments. His expertise in antibiotic therapies has positioned him as a valuable asset in the field.

Collaborations

Francis Arhin has collaborated with Gregory Moeck, a fellow professional in the industry. Their partnership has likely fostered advancements in research and development, particularly in the area of antibiotic treatments.

Conclusion

Francis Arhin's contributions to the field of medicine through his innovative patent and collaborations highlight his commitment to improving healthcare. His work continues to influence the treatment of bacterial infections, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…